Latest Opioid Stories

CAMBRIDGE, England, April 21, 2011 /PRNewswire/ -- - First-time-in-man Study Initiated Ahead of Schedule Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun. The trial is a randomised, placebo...

SAN FRANCISCO, April 18, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2011 on Wednesday, April 27, 2011, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). The press release and a live audio-only Webcast of the conference call can be...

NATIONAL HARBOR, Md., March 24, 2011 /PRNewswire-USNewswire/ -- Results from a small study of intractable pain patients being treated with the human chorionic gonadotropin (HCG) hormone reported that they had experienced pain free hours in the past month. These results were presented today at a poster session at the American Academy of Pain Medicine's 27th Annual Meeting. Forest Tennant M.D., Ph.D., of the Veract Intractable Pain Clinic in West Covina, California, presented the results....

BALTIMORE, March 24, 2011 /PRNewswire/ -- An educational symposium at the American Academy of Pain Medicine's Annual Meeting will give attendees the opportunity to learn more about the landscape of chronic opioid therapy. The dinner symposium, entitled "The Evolving Landscape of Chronic Opioid Therapy and Risk Management" and sponsored by Ameritox, will address changes in the treatment landscape of chronic opioid therapy. The event will be held Saturday, March 26 at 5:30 p.m. in Woodrow...

Results from a new study suggest that one of the most prescribed medications for alcohol dependence may be more effective in some people. Preliminary results show that naltrexone (Revia), one of the only medications approved for treating people with alcohol abuse problems, may only be effective in women and those with a specific genetic variation. The new study, conducted by researchers from the Research Institute of the McGill University Health Centre (RI MUHC) and McGill University, will be...

    * Naltrexone is one of the most effective pharmacological treatments for alcohol dependence.    * However, naltrexone does not work for everyone.    * A new study has found that naltrexone is effective for women, and individuals with the A118G polymorphism of the mu opioid receptor gene (OPRM1). There are few pharmacological treatments for alcohol dependence (AD). An opioid receptor antagonist called naltrexone is one of the most effective, and yet it is not...

RALEIGH, N.C., March 11, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announces that it has received definitive commitments from institutional investors for a private placement financing yielding gross proceeds of $15 million to BDSI. The financing is expected to close today. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Under the terms of a securities purchase agreement entered into with the investors, BDSI will sell an aggregate of...

GLEN ALLEN, Va., March 8, 2011 /PRNewswire/ -- The National Association of Managed Care Physicians (NAMCP) Medical Directors Research Institute announced that Matt Hughes, MD, MPH, Associate Professor Division of Occupational & Environmental Medicine University of Utah School of Medicine will present "Comparative Evaluation of Treatment Guidelines for Chronic Opioid Use in Non-Malignant Pain Disorders: Identification of Responsible Opioid Prescribing and Utilization Practices" at 9:30...

RALEIGH, N.C., March 2, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the positive outcome of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on the development program for BEMA Buprenorphine/Naloxone, BDSI's potential treatment for opioid dependence. The development program discussed is based on pharmacokinetic and safety data for a 505(b)(2) New Drug Application (NDA). (Logo:...

SAN FRANCISCO, March 1, 2011 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the 31st Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 8, 2011 at 11:00 a.m. Eastern time. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast...